32 results on '"Söhler, Sandra"'
Search Results
2. Cumulative occupational exposure to gases and fumes is associated with impairment in lung function and disease-related quality of life in a German COPD patient cohort
- Author
-
IRAS OH Epidemiology Chemical Agents, IRAS – One Health Chemical, Gerlich, Jessica, Ohlander, Johan, Kromhout, Hans, Vermeulen, Roel, Söhler, Sandra, Radon, Katja, Nowak, Dennis, Karrasch, Stefan, Adaskina, Nina, Vogelmeier, Claus, Ochmann, Uta, Jörres, Rudolf A, IRAS OH Epidemiology Chemical Agents, IRAS – One Health Chemical, Gerlich, Jessica, Ohlander, Johan, Kromhout, Hans, Vermeulen, Roel, Söhler, Sandra, Radon, Katja, Nowak, Dennis, Karrasch, Stefan, Adaskina, Nina, Vogelmeier, Claus, Ochmann, Uta, and Jörres, Rudolf A
- Published
- 2024
3. Cumulative occupational exposure to gases and fumes is associated with impairment in lung function and disease-related quality of life in a German COPD patient cohort
- Author
-
Gerlich, Jessica, primary, Ohlander, Johan, additional, Kromhout, Hans, additional, Vermeulen, Roel, additional, Söhler, Sandra, additional, Radon, Katja, additional, Nowak, Dennis, additional, Karrasch, Stefan, additional, Adaskina, Nina, additional, Vogelmeier, Claus, additional, Ochmann, Uta, additional, and Jörres, Rudolf A, additional
- Published
- 2023
- Full Text
- View/download PDF
4. Characteristics of Current Smokers versus Former Smokers with COPD and Their Associations with Smoking Cessation Within 4.5 Years: Results from COSYCONET
- Author
-
Alter, Peter, primary, Stoleriu, Cosmina, additional, Kahnert, Kathrin, additional, Henke, Markus, additional, Bals, Robert, additional, Trudzinski, Franziska, additional, Watz, Henrik, additional, Speicher, Tim, additional, Söhler, Sandra, additional, Welte, Tobias, additional, Rabe, Klaus, additional, Wouters, Emiel, additional, Vogelmeier, Claus, additional, and Jörres, Rudolf, additional
- Published
- 2023
- Full Text
- View/download PDF
5. CAT score single item analysis in patients with COPD: Results from COSYCONET
- Author
-
Stefan, Andreas, Robert, Bals, Jürgen, Behr, Kathrin, Kahnert, Burkhard, Bewig, Roland, Buhl, Ralf, Ewert, Beate, Stubbe, Ficker, Joachim H., Manfred, Gogol, Christian, Grohé, Rainer, Hauck, Matthias, Held, Berthold, Jany, Markus, Henke, Felix, Herth, Gerd, Höffken, Katus Hugo, A., Anne-Marie, Kirsten, Henrik, Watz, Rembert, Koczulla, Klaus, Kenn, Juliane, Kronsbein, Cornelia, Kropf-Sanchen, Christoph, Lange, Peter, Zabel, Michael, Pfeifer, Randerath Winfried, J., Werner, Seeger, Michael, Studnicka, Christian, Taube, Helmut, Teschler, Hartmut, Timmermann, Christian, Virchow J., Claus, Vogelmeier, Ulrich, Wagner, Tobias, Welte, Hubert, Wirtz, Lehnert, Doris, Struck, Birte, Krabbe, Lenka, Arikan, Barbara, Tobias, Julia, Speth, Kornelia, Pieper, Jeanette, Gleiniger, Margret, Markworth, Britta, Hinz, Zaklina, Burmann, Ellen, Wons, Katrin, Rieber, Ulrike, Schaufler, Beate, Schwedler, Katrin, Michalewski, Sabine, Rohweder, Sonja, Berger, Patricia, Schottel, Diana, Janke, Vivien, Untsch, Rosalie, Graf, Jana, Reichel, Anita, Weiß, Gertraud, Traugott, Erich, Kietzmann, Ilona, Schrade-Illmann, Michaela, Polte, Beate, Hübner, Gudrun, Marietta von Siemens, Sarah, Alter, Peter, Lutter, Johanna I., Kauczor, Hans-Ulrich, Jobst, Bertram, Bals, Robert, Trudzinski, Franziska C., Söhler, Sandra, Behr, Jürgen, Watz, Henrik, Waschki, Benjamin, Bewig, Burkhard, Jones, Paul W., Welte, Tobias, Vogelmeier, Claus F., Jörres, Rudolf A., and Kahnert, Kathrin
- Published
- 2019
- Full Text
- View/download PDF
6. Midregional pro atrial naturetic peptide (MRproANP) and copeptin (COPAVP) as predictors of all- cause mortality in early COPD – Results from COSYCONET
- Author
-
Fähndrich, Sebastian, primary, Herr, Christian, additional, Teuteberg, Sebastian, additional, Alter, Peter, additional, Söhler, Sandra, additional, Soriano, Daniel, additional, Classen, Johanna, additional, Adams, Julia, additional, Weinhold, Victoria, additional, Watz, Henrik, additional, Waschki, Benjamin, additional, Zeller, Tanja, additional, Eichenlaub, Martin, additional, Trudzinski, Franziska C, additional, Michels, Julia D, additional, Omlor, Albert, additional, Seiler, Frederik, additional, Moneke, Isabelle, additional, Biertz, Frank, additional, Stolz, Daiana, additional, Welte, Tobias, additional, Kauczor, Hans-Ulrich, additional, Kahnert, Kathrin, additional, Jörres, Rudolf A, additional, vogelmeier, claus, additional, bals, robert, additional, and group, COSYCONET study, additional
- Published
- 2023
- Full Text
- View/download PDF
7. Clinical factors linked to the type of respiratory medication in COPD: Results from COSYCONET
- Author
-
Alter, Peter, primary, Kahnert, Kathrin, additional, Trudzinski, Franziska C., additional, Bals, Robert, additional, Watz, Henrik, additional, Speicher, Tim, additional, Söhler, Sandra, additional, Welte, Tobias, additional, Rabe, Klaus F. R., additional, Wouters, Emiel F. M., additional, Vogelmeier, Claus F., additional, and Jörres, Rudolf A., additional
- Published
- 2023
- Full Text
- View/download PDF
8. Proteasome function as a biomarker for severe COPD endotypes
- Author
-
Flexeder, Claudia, primary, Kammerl, Ilona, additional, Karrasch, Stefan, additional, Pedersen, Frauke, additional, Vogelmeier, Claus, additional, Behr, Jürgen, additional, Söhler, Sandra, additional, Watz, Henrik, additional, Peters, Annette, additional, Schulz, Holger, additional, and Meiners, Silke, additional
- Published
- 2023
- Full Text
- View/download PDF
9. Cumulative occupational exposure to gases and fumes is associated with impairment in lung function and disease-related quality of life in a German COPD patient cohort.
- Author
-
Gerlich, Jessica, Ohlander, Johan, Kromhout, Hans, Vermeulen, Roel, Söhler, Sandra, Radon, Katja, Nowak, Dennis, Karrasch, Stefan, Adaskina, Nina, Vogelmeier, Claus, Ochmann, Uta, and Jörres, Rudolf A.
- Published
- 2024
- Full Text
- View/download PDF
10. Clinical factors linked to the type of respiratory medication in COPD: results from the COSYCONET cohort.
- Author
-
Alter, Peter, Kahnert, Kathrin, Trudzinski, Franziska C., Bals, Robert, Watz, Henrik, Speicher, Tim, Söhler, Sandra, Welte, Tobias, Rabe, Klaus F., Wouters, Emiel F. M., Vogelmeier, Claus F., and Jörres, Rudolf A.
- Subjects
OBSTRUCTIVE lung diseases ,CHRONIC obstructive pulmonary disease ,STAIR climbing ,DRUGS - Abstract
Background: The use of maintenance medication in patients with chronic obstructive pulmonary disease (COPD) in real life is known to deviate from recommendations in guidelines, which are largely based on randomized controlled trials and selected populations. Objectives: We used the COSYCONET (CO PD and Sy stemic Consequences – Co morbidities Net work) cohort to analyze factors linked to the use of COPD drugs under non-interventional circumstances. Design: COSYCONET is an ongoing, multi-center, non-interventional cohort of patients with COPD. Methods: Patients with COPD of Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades 0–4 participating in visits 1–5 were included. Data covered the period from 2010 to 2018. Generalized linear models were used to examine the relation of COPD characteristics to different types of respiratory medication. Results: A total of 1043 patients were included. The duration of observation was 4.5 years. Use of respiratory medication depended on GOLD grades 0–4 and groups A-D. Long-acting muscarinic antagonist therapy increased over time, and was associated with low carbon monoxide (CO) diffusing capacity, while inhaled corticosteroid (ICS) use decreased. Active smoking was associated with less maintenance therapy in general, and female sex with less ICS use. From the eight items of the COPD Assessment Test, only hill and stair climbing were consistently linked to treatment. Conclusion: Using data from a large, close to real-life observational cohort, we identified factors linked to the use of various types of respiratory COPD medication. Overall, use was consistent with GOLD recommendations. Beyond this, we identified other correlates of medication use that may help us to understand and improve therapy decisions in clinical practice. Trial registration: ClinicalTrials.gov NCT01245933. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline
- Author
-
Karch, Annika, Vogelmeier, Claus, Welte, Tobias, Bals, Robert, Kauczor, Hans-Ulrich, Biederer, Jürgen, Heinrich, Joachim, Schulz, Holger, Gläser, Sven, Holle, Rolf, Watz, Henrik, Korn, Stephanie, Adaskina, Nina, Biertz, Frank, Vogel, Charlotte, Vestbo, Jørgen, Wouters, Emiel F.M., Rabe, Klaus Friedrich, Söhler, Sandra, Koch, Armin, and Jörres, Rudolf A.
- Published
- 2016
- Full Text
- View/download PDF
12. Was haben wir aus der deutschen COPD-Kohorte COSYCONET gelernt und wie geht es weiter?
- Author
-
Kahnert, Kathrin, additional, Fischer, Carolina, additional, Alter, Peter, additional, Trudzinski, Franziska, additional, Welte, Tobias, additional, Behr, Jürgen, additional, Herth, Felix, additional, Kauczor, Hans-Ulrich, additional, Bals, Robert, additional, Watz, Henrik, additional, Rabe, Klaus, additional, Söhler, Sandra, additional, Kokot, Inge, additional, Vogelmeier, Claus, additional, and Jörres, Rudolf, additional
- Published
- 2022
- Full Text
- View/download PDF
13. The association of cognitive functioning as measured by the DemTect with functional and clinical characteristics of COPD: results from the COSYCONET cohort
- Author
-
von Siemens, Sarah Marietta, Perneczky, Robert, Waschki, Benjamin, Lutter, Johanna I, Welte, Tobias, Jörres, Rudolf A, Kahnert, Kathrin, group, COSYCONET study, Andreas, Stefan, Bals, Robert, Behr, Jürgen, Vogelmeier, Claus F, Bewig, Burkhard, Buhl, Roland, Ewert, Ralf, Stubbe, Beate, Gogol, Manfred, Grohé, Christian, Hauck, Rainer, Held, Matthias, Jany, Berthold, Henke, Markus, Herth, Felix, Höffken, Gerd, Katus, Hugo A, Kirsten, Anne-Marie, Watz, Henrik, Koczulla, Rembert, Kenn, Klaus, Kronsbein, Juliane, Kropf-Sanchen, Cornelia, Lange, Christoph, Kauffmann-Guerrero, Diego, Zabel, Peter, Pfeifer, Michael, Randerath, Winfried J, Seeger, Werner, Studnicka, Michael, Taube, Christian, Teschler, Helmut, Timmermann, Hartmut, Virchow, J Christian, Vogelmeier, Claus, Alter, Peter, Wagner, Ulrich, Wirtz, Hubert, Trudzinski, Franziska C, and Söhler, Sandra
- Subjects
Male ,medicine.medical_specialty ,epidemiology [Cognitive Dysfunction] ,psychology [Pulmonary Disease, Chronic Obstructive] ,Medizin ,Comorbidity ,Cohort Studies ,03 medical and health sciences ,FEV1/FVC ratio ,Pulmonary Disease, Chronic Obstructive ,0302 clinical medicine ,Cognition ,epidemiology [Pulmonary Disease, Chronic Obstructive] ,Surveys and Questionnaires ,medicine ,Dementia ,Humans ,COPD ,Cognitive Dysfunction ,ddc:610 ,Cognitive skill ,Path analysis (statistics) ,Aged ,lcsh:RC705-779 ,business.industry ,Research ,physiology [Cognition] ,diagnosis [Pulmonary Disease, Chronic Obstructive] ,lcsh:Diseases of the respiratory system ,Middle Aged ,medicine.disease ,Mental Status and Dementia Tests ,humanities ,Cross-Sectional Studies ,Cognitive impairment ,diagnosis [Cognitive Dysfunction] ,030228 respiratory system ,Cohort ,Physical therapy ,Female ,psychology [Cognitive Dysfunction] ,business ,030217 neurology & neurosurgery ,Cognitive load - Abstract
Alterations of cognitive functions have been described in COPD. Our study aimed to disentangle the relationship between the degree of cognitive function and COPD characteristics including quality of life (QoL).Data from 1969 COPD patients of the COSYCONET cohort (GOLD grades 1–4; 1216 male/ 753 female; mean (SD) age 64.9 ± 8.4 years) were analysed using regression and path analysis. The DemTect screening tool was used to measure cognitive function, and the St. George‘s respiratory questionnaire (SGRQ) to assess disease-specific QoL.DemTect scores were =60 years of age. For statistical reasons, we used the average of both algorithms independent of age in all subsequent analyses. The DemTect scores were associated with oxygen content, 6-min-walking distance (6-MWD), C-reactive protein (CRP), modified Medical Research Council dyspnoea scale (mMRC) and the SGRQ impact score. Conversely, the SGRQ impact score was independently associated with 6-MWD, FVC, mMRC and DemTect. These results were combined into a path analysis model to account for direct and indirect effects. The DemTect score had a small, but independent impact on QoL, irrespective of the inclusion of COPD-specific influencing factors or a diagnosis of cognitive impairment.We conclude that in patients with stable COPD lower oxygen content of blood as a measure of peripheral oxygen supply, lower exercise capacity in terms of 6-MWD, and higher CRP levels were associated with reduced cognitive capacity. Furthermore, a reduction in cognitive capacity was associated with reduced disease-specific quality of life. As a potential clinical implication of this work, we suggest to screen especially patients with low oxygen content and low 6-MWD for cognitive impairment.
- Published
- 2022
- Full Text
- View/download PDF
14. Disease Progression and Age as Factors Underlying Multimorbidity in Patients with COPD: Results from COSYCONET
- Author
-
Alter, Peter, primary, Kahnert, Kathrin, additional, Trudzinski, Franziska C, additional, Bals, Robert, additional, Watz, Henrik, additional, Speicher, Tim, additional, Söhler, Sandra, additional, Andreas, Stefan, additional, Welte, Tobias, additional, Rabe, Klaus F, additional, Wouters, Emiel FM, additional, Sassmann-Schweda, Antonia, additional, Wirtz, Hubert, additional, Ficker, Joachim H, additional, Vogelmeier, Claus F, additional, and Jörres, Rudolf A, additional
- Published
- 2022
- Full Text
- View/download PDF
15. Was haben wir aus der deutschen COPD-Kohorte COSYCONET gelernt und wie geht es weiter?
- Author
-
Kahnert, Kathrin, Fischer, Carolina, Alter, Peter, Trudzinski, Franziska, Welte, Tobias, Behr, Jürgen, Herth, Felix, Kauczor, Hans-Ulrich, Bals, Robert, Watz, Henrik, Rabe, Klaus, Söhler, Sandra, Kokot, Inge, Vogelmeier, Claus, and Jörres, Rudolf
- Published
- 2023
- Full Text
- View/download PDF
16. Late Breaking Abstract - Chronic coronary artery disease and decline of lung function as predictors of mortality and exacerbation risk in stable COPD: Results from COSYCONET
- Author
-
Alter, Peter, primary, Lucke, Tanja, additional, Watz, Henrik, additional, Andreas, Stefan, additional, Kahnert, Kathrin, additional, Trudzinski, Franziska, additional, Speicher, Tim, additional, Söhler, Sandra, additional, Bals, Robert, additional, Welte, Tobias, additional, Rabe, Klaus, additional, Vestbo, Jørgen, additional, Wouters, Emiel, additional, Vogelmeier, Claus, additional, and Jörres, Rudolf, additional
- Published
- 2021
- Full Text
- View/download PDF
17. Impact of the COVID-19 pandemic on the behaviour and health status of patients with COPD: results from the German COPD cohort COSYCONET
- Author
-
Kahnert, Kathrin, primary, Lutter, Johanna I., additional, Welte, Tobias, additional, Alter, Peter, additional, Behr, Jürgen, additional, Herth, Felix, additional, Kauczor, Hans-Ulrich, additional, Söhler, Sandra, additional, Pfeifer, Michael, additional, Watz, Henrik, additional, Vogelmeier, Claus F., additional, Bals, Robert, additional, Jörres, Rudolf A., additional, and Trudzinski, Franziska C., additional
- Published
- 2021
- Full Text
- View/download PDF
18. CAT score single item analysis in patients with COPD: Results from COSYCONET
- Author
-
Marietta von Siemens, Sarah, primary, Alter, Peter, additional, Lutter, Johanna I., additional, Kauczor, Hans-Ulrich, additional, Jobst, Bertram, additional, Bals, Robert, additional, Trudzinski, Franziska C., additional, Söhler, Sandra, additional, Behr, Jürgen, additional, Watz, Henrik, additional, Waschki, Benjamin, additional, Bewig, Burkhard, additional, Jones, Paul W., additional, Welte, Tobias, additional, Vogelmeier, Claus F., additional, Jörres, Rudolf A., additional, Kahnert, Kathrin, additional, Stefan, Andreas, additional, Robert, Bals, additional, Jürgen, Behr, additional, Kathrin, Kahnert, additional, Burkhard, Bewig, additional, Roland, Buhl, additional, Ralf, Ewert, additional, Beate, Stubbe, additional, Ficker, Joachim H., additional, Manfred, Gogol, additional, Christian, Grohé, additional, Rainer, Hauck, additional, Matthias, Held, additional, Berthold, Jany, additional, Markus, Henke, additional, Felix, Herth, additional, Gerd, Höffken, additional, Katus Hugo, A., additional, Anne-Marie, Kirsten, additional, Henrik, Watz, additional, Rembert, Koczulla, additional, Klaus, Kenn, additional, Juliane, Kronsbein, additional, Cornelia, Kropf-Sanchen, additional, Christoph, Lange, additional, Peter, Zabel, additional, Michael, Pfeifer, additional, Randerath Winfried, J., additional, Werner, Seeger, additional, Michael, Studnicka, additional, Christian, Taube, additional, Helmut, Teschler, additional, Hartmut, Timmermann, additional, Christian, Virchow J., additional, Claus, Vogelmeier, additional, Ulrich, Wagner, additional, Tobias, Welte, additional, Hubert, Wirtz, additional, Lehnert, Doris, additional, Struck, Birte, additional, Krabbe, Lenka, additional, Arikan, Barbara, additional, Tobias, Julia, additional, Speth, Kornelia, additional, Pieper, Jeanette, additional, Gleiniger, Margret, additional, Markworth, Britta, additional, Hinz, Zaklina, additional, Burmann, Ellen, additional, Wons, Katrin, additional, Rieber, Ulrike, additional, Schaufler, Beate, additional, Schwedler, Katrin, additional, Michalewski, Sabine, additional, Rohweder, Sonja, additional, Berger, Patricia, additional, Schottel, Diana, additional, Janke, Vivien, additional, Untsch, Rosalie, additional, Graf, Jana, additional, Reichel, Anita, additional, Weiß, Gertraud, additional, Traugott, Erich, additional, Kietzmann, Ilona, additional, Schrade-Illmann, Michaela, additional, Polte, Beate, additional, and Hübner, Gudrun, additional
- Published
- 2019
- Full Text
- View/download PDF
19. Adherence to respiratory and non-respiratory medication in patients with COPD: Results of the German COSYCONET cohort
- Author
-
Königsdorfer, Norbert, Jörres, Rudolf A., Söhler, Sandra, Welte, Tobias, Behr, Jürgen, Ficker, Joachim H., Bals, Robert, Watz, Henrik, Lutter, Johanna I., Lucke, Tanja, Biertz, Frank, Alter, Peter, Vogelmeier, Claus F., and Kahnert, Kathrin
- Subjects
lcsh:R5-920 ,respiratory medication ,Patient Preference and Adherence ,COPD ,treatment adherence ,lcsh:Medicine (General) ,non-respiratory medication ,nonrespiratory medication ,Copd ,Nonrespiratory Medication ,Respiratory Medication ,Treatment Adherence - Abstract
Norbert Königsdorfer,1 Rudolf A Jörres,1 Sandra Söhler,2 Tobias Welte,3 Jürgen Behr,4 Joachim H Ficker,5 Robert Bals,6 Henrik Watz,7 Johanna I Lutter,8 Tanja Lucke,1 Frank Biertz,9 Peter Alter,10 Claus F Vogelmeier,10 Kathrin Kahnert4 1Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Comprehensive Pneumology Center Munich (CPC-M), Ludwig-Maximilians-Universität München, Munich 80336, Germany; 2ASCONET Study Coordination Office, University of Marburg, Marburg 35043, Germany; 3Department of Pneumology, Hannover Medical School, Hannover 30625, Germany; 4Department of Internal Medicine V, University of Munich, Comprehensive Pneumology Center, Member of the German Center for Lung Research, Munich 80336, Germany; 5Department of Respiratory Medicine, Allergology and Sleep Medicine, General Hospital Nuernberg, Paracelsus Medical University, Nuernberg, Germany; 6Department of Internal Medicine V, Pneumology, Allergology, Respiratory Intensive Care Medicine, Saarland University Hospital, Homburg 66424, Germany; 7Pulmonary Research Institute at LungenClinic Grosshansdorf, Airway Research Center North, Member of the German Center for Lung Research, Grosshansdorf 22927, Germany; 8Institute of Health Economics and Health Care Management, Helmholtz Zentrum München GmbH – German Research Center for Environmental Health, Comprehensive Pneumology Center Munich (CPC-M), Munich 85764, Germany; 9Institute for Biostatistics, Hannover Medical School, Hannover 30625, Germany; 10Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Marburg 35043, GermanyCorrespondence: Kathrin KahnertDepartment of Internal Medicine V, University of Munich, Comprehensive Pneumology Center, Member of the German Center for Lung Research, Ziemssenstr. 1, Munich 80336, GermanyTel +49 89 4400 2590Email Kathrin.Kahnert@med.uni-muenchen.deBackground: Adherence to COPD medication is often considered to be lower than in other chronic diseases. In view of the frequent comorbidities of COPD, the economic impact of nonadherence and the potential for adverse effects, a direct comparison between the adherence to respiratory and nonrespiratory medication in the same patients seems of particular interest.Objectives: We aimed to investigate the intake of respiratory and nonrespiratory medication in the same patients with COPD and frequent comorbidities.Method: Within the COPD cohort COSYCONET, we contacted 1042 patients, mailing them a list with all medication regarding all their diseases, asking for regular, irregular and non-intake.Results: Valid responses were obtained in 707 patients covering a wide spectrum of drugs. Intake of LABA, LAMA or ICS was regular in 91.9% of patients, even higher for cardiovascular and antidiabetes medication but lower for hyperlipidemia and depression/anxiety medication. Regular intake of respiratory medication did not depend on GOLD groups A-D or grades 1–4, was highest in patients with concomitant cardiovascular disorders and was lowest for concomitant asthma. It was slightly larger for LAMA and LABA administered via combined compared to single inhalers, and lower when similar compounds were prescribed twice. Most differences did not reach statistical significance owing to the overall high adherence.Conclusion: Our results indicate a high adherence to respiratory medication in participants of a COPD cohort, especially in those with cardiovascular comorbidities. Compared to the lower adherence reported in the literature for COPD patients, our observations still suggest some room for improvement, possibly through disease management programs.Keywords: COPD, treatment adherence, respiratory medication, nonrespiratory medication
- Published
- 2019
20. Adherence To Respiratory And Nonrespiratory Medication In Patients With COPD: Results Of The German COSYCONET Cohort
- Author
-
Königsdorfer, Norbert, primary, Jörres, Rudolf A, additional, Söhler, Sandra, additional, Welte, Tobias, additional, Behr, Jürgen, additional, Ficker, Joachim H, additional, Bals, Robert, additional, Watz, Henrik, additional, Lutter, Johanna I, additional, Lucke, Tanja, additional, Biertz, Frank, additional, Alter, Peter, additional, Vogelmeier, Claus F, additional, and Kahnert, Kathrin, additional
- Published
- 2019
- Full Text
- View/download PDF
21. Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort
- Author
-
Kahnert, Kathrin, Lucke, Tanja, Biertz, Frank, Lechner, Andreas, Watz, Henrik, Alter, Peter, Bals, Robert, Behr, Jürgen, Holle, Rolf, Huber, Rudolf M., Karrasch, Stefan, Stubbe, Beate, Wacker, Margarethe, Söhler, Sandra, Wouters, Emiel F. M., Vogelmeier, Claus, Jörres, Rudolf A., MUMC+: MA Longziekten (3), RS: NUTRIM - R3 - Respiratory & Age-related Health, Pulmonologie, and RS: NUTRIM - R3 - Chronic inflammatory disease and wasting
- Subjects
Pulmonary and Respiratory Medicine ,Male ,METFORMIN ,Comorbidity ,Sensitivity and Specificity ,OBSTRUCTIVE PULMONARY-DISEASE ,CAPACITY ,Cohort Studies ,Pulmonary Disease, Chronic Obstructive ,MELLITUS ,INFLAMMATION ,Risk Factors ,Germany ,Diabetes Mellitus ,Prevalence ,Humans ,COPD ,MACROPHAGES ,Aged ,Diffusing capacity ,Carbon Monoxide ,Research ,MORTALITY ,Diabetes ,Reproducibility of Results ,respiratory system ,Carbon Dioxide ,Middle Aged ,Lung function ,REFERENCE VALUES ,respiratory tract diseases ,LUNG-FUNCTION ,FACTOR-KAPPA-B ,Copd ,Diffusing Capacity ,Lung Function ,Pulmonary Diffusing Capacity ,Female - Abstract
Background: An impairment of CO diffusing capacity has been shown in diabetic patients without lung disease. We analyzed how diffusing capacity in patients with COPD is affected by the concurrent diagnosis of diabetes. Methods: Data from the initial visit of the German COPD cohort COSYCONET were used for analysis. 2575 patients with complete lung function data were included, among them 358 defined as diabetics with a reported physician diagnosis of diabetes and/or specific medication. Pairwise comparisons between groups and multivariate regression models were used to identify variables predicting the CO transfer factor (TLCO% pred) and the transfer coefficient (KCO% pred). Results: COPD patients with diabetes differed from those without diabetes regarding lung function, anthropometric, clinical and laboratory parameters. Moreover, gender was an important covariate. After correction for lung function, gender and body mass index (BMI), TLCO% pred did not significantly differ between patients with and without diabetes. The results for the transfer coefficient KCO were similar, demonstrating an important role of the confounding factors RV% pred, TLC% pred, ITGV% pred, FEV1% pred, FEV1/FVC, age, packyears, creatinine and BMI. There was not even a tendency towards lower values in diabetes. Conclusion: The analysis of data from a COPD cohort showed no significant differences of CO transport parameters between COPD patients with and without diabetes, if BMI, gender and the reduction in lung volumes were taken into account. This result is in contrast to observations in lung-healthy subjects with diabetes and raises the question which factors, among them potential anti-inflammatory effects of anti-diabetes medication are responsible for this finding.
- Published
- 2017
22. Relationship of hyperlipidemia to comorbidities and lung function in COPD: results of the COSYCONET cohort
- Author
-
Kahnert, Kathrin, primary, Lucke, Tanja, additional, Huber, Rudolf M., additional, Behr, Jürgen, additional, Biertz, Frank, additional, Vogt, Anja, additional, Watz, Henrik, additional, Alter, Peter, additional, Fähndrich, Sebastian, additional, Bals, Robert, additional, Holle, Rolf, additional, Karrasch, Stefan, additional, Söhler, Sandra, additional, Wacker, Margarethe, additional, Ficker, Joachim H., additional, Parhofer, Klaus, additional, Vogelmeier, Claus, additional, and Jörres, Rudolf A., additional
- Published
- 2017
- Full Text
- View/download PDF
23. Disease-specific medication, patient-reported diagnoses and their relation to COPD severity for common comorbidities in COPD
- Author
-
Lucke, Tanja, primary, Herrera, Ronald, additional, Wacker, Margarethe, additional, Holle, Rolf, additional, Biertz, Frank, additional, Nowak, Dennis, additional, Kahnert, Kathrin, additional, Huber, Rudolf M, additional, Söhler, Sandra, additional, Alter, Peter, additional, Vogelmeier, Claus, additional, Ficker, Joachim H, additional, and Jörres, Rudolf A, additional
- Published
- 2017
- Full Text
- View/download PDF
24. COPD influences on left heart wall stress — An analysis of the COSYCONET cohort
- Author
-
Alter, Peter, primary, Watz, Henrik, additional, Welte, Tobias, additional, Gläser, Sven, additional, Schulz, Holger, additional, Bals, Robert, additional, Söhler, Sandra, additional, Karch, Annika, additional, Vogelmeier, Claus, additional, and Jörres, Rudolf, additional
- Published
- 2016
- Full Text
- View/download PDF
25. Prevalence of common diseases in COPD patients versus lung-healthy control subjects: Results from the German COSYCONET study
- Author
-
Karrasch, Stefan, primary, Obst, Anne, additional, Söhler, Sandra, additional, Thorand, Barbara, additional, Huth, Cornelia, additional, Ladwig, Karl-Heinz, additional, Flexeder, Claudia, additional, Wacker, Margarethe, additional, Peters, Annette, additional, Heinrich, Joachim, additional, Ewert, Ralf, additional, Nowak, Dennis, additional, Jörres, Rudolf A., additional, Vogelmeier, Claus, additional, Gläser, Sven, additional, and Schulz, Holger, additional
- Published
- 2016
- Full Text
- View/download PDF
26. Systematic analysis of self-reported comorbidities in the COSYCONET COPD cohort study by stepwise evaluation of medication
- Author
-
Lucke, Tanja, primary, Herrera, Ronald, additional, Wacker, Margarethe, additional, Holle, Rolf, additional, Biertz, Frank, additional, Nowak, Dennis, additional, Huber, Rudolf Maria, additional, Söhler, Sandra, additional, Vogelmeier, Claus, additional, Ficker, Joachim, additional, Mückter, Harald, additional, and Jörres, Rudolf A., additional
- Published
- 2016
- Full Text
- View/download PDF
27. Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort.
- Author
-
Kahnert, Kathrin, Lucke, Tanja, Huber, Rudolf M., Behr, Jürgen, Biertz, Frank, Vogt, Anja, Watz, Henrik, Alter, Peter, Fähndrich, Sebastian, Bals, Robert, Holle, Rolf, Karrasch, Stefan, Söhler, Sandra, Wacker, Margarethe, Ficker, Joachim H., Parhofer, Klaus G., Vogelmeier, Claus, Jörres, Rudolf A., and null, null
- Subjects
OBSTRUCTIVE lung diseases ,HYPERLIPIDEMIA ,LUNG physiology ,HYPERTENSION ,AGE factors in disease ,DISEASE risk factors - Abstract
Although hyperlipidemia is common in COPD, its relationship to comorbidities, risk factors and lung function in COPD has not been studied in detail. Using the baseline data of the COSYCONET cohort we addressed this question. Data from 1746 COPD patients (GOLD stage 1–4; mean age 64.6 y, mean FEV1%pred 57%) were evaluated, focusing on the comorbidities hyperlipidemia, diabetes and cardiovascular complex (CVC; including arterial hypertension, cardiac failure, ischemic heart disease). Risk factors comprised age, gender, BMI, and packyears of smoking. The results of linear and logistic regression analyses were implemented into a path analysis model describing the multiple relationships between parameters. Hyperlipidemia (prevalence 42.9%) was associated with lower intrathoracic gas volume (ITGV) and higher forced expiratory volume in 1 second (FEV
1 ) when adjusting for its multiple relationships to risk factors and other comorbidities. These findings were robust in various statistical analyses. The associations between comorbidities and risk factors were in accordance with previous findings, thereby underlining the validity of our data. In conclusion, hyperlipidemia was associated with less hyperinflation and airway obstruction in patients with COPD. This surprising result might be due to different COPD phenotypes in these patients or related to effects of medication. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
28. Systematic Analysis of Self-Reported Comorbidities in Large Cohort Studies - A Novel Stepwise Approach by Evaluation of Medication.
- Author
-
Lucke, Tanja, Herrera, Ronald, Wacker, Margarethe, Holle, Rolf, Biertz, Frank, Nowak, Dennis, Huber, Rudolf M., Söhler, Sandra, Vogelmeier, Claus, Ficker, Joachim H., Mückter, Harald, and Jörres, Rudolf A.
- Subjects
COMORBIDITY ,MEDICAL records ,OBSTRUCTIVE lung diseases ,CARDIOVASCULAR diseases ,DYSLIPIDEMIA - Abstract
Objective In large cohort studies comorbidities are usually self-reported by the patients. This way to collect health information only represents conditions known, memorized and openly reported by the patients. Several studies addressed the relationship between self-reported comorbidities and medical records or pharmacy data, but none of them provided a structured, documented method of evaluation. We thus developed a detailed procedure to compare self-reported comorbidities with information on comorbidities derived from medication inspection. This was applied to the data of the German COPD cohort COSYCONET. Methods Approach I was based solely on ICD10-Codes for the diseases and the indications of medications. To overcome the limitations due to potential non-specificity of medications, Approach II was developed using more detailed information, such as ATC-Codes specific for one disease. The relationship between reported comorbidities and medication was expressed by a four-level concordance score. Results Approaches I and II demonstrated that the patterns of concordance scores markedly differed between comorbidities in the COSYCONET data. On average, Approach I resulted in more than 50% concordance of all reported diseases to at least one medication. The more specific Approach II showed larger differences in the matching with medications, due to large differences in the disease-specificity of drugs. The highest concordance was achieved for diabetes and three combined cardiovascular disorders, while it was substantial for dyslipidemia and hyperuricemia, and low for asthma. Conclusion Both approaches represent feasible strategies to confirm self-reported diagnoses via medication. Approach I covers a broad spectrum of diseases and medications but is limited regarding disease-specificity. Approach II uses the information from medications specific for a single disease and therefore can reach higher concordance scores. The strategies described in a detailed and reproducible manner are generally applicable in large studies and might be useful to extract as much information as possible from the available data. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
29. The association of cognitive functioning as measured by the DemTect with functional and clinical characteristics of COPD: results from the COSYCONET cohort.
- Author
-
von Siemens, Sarah Marietta, Perneczky, Robert, Vogelmeier, Claus F., Behr, Jürgen, Kauffmann-Guerrero, Diego, Alter, Peter, Trudzinski, Franziska C., Bals, Robert, Grohé, Christian, Söhler, Sandra, Waschki, Benjamin, Lutter, Johanna I., Welte, Tobias, Jörres, Rudolf A., Kahnert, Kathrin, the COSYCONET study group, Andreas, Stefan, Bewig, Burkhard, Buhl, Roland, and Ewert, Ralf
- Subjects
COGNITIVE ability ,COGNITION disorders ,PATH analysis (Statistics) ,MONTREAL Cognitive Assessment ,OXYGEN in the blood ,CHARACTERISTIC functions ,BLOOD lactate - Abstract
Alterations of cognitive functions have been described in COPD. Our study aimed to disentangle the relationship between the degree of cognitive function and COPD characteristics including quality of life (QoL).Data from 1969 COPD patients of the COSYCONET cohort (GOLD grades 1-4; 1216 male/ 753 female; mean (SD) age 64.9 ± 8.4 years) were analysed using regression and path analysis. The DemTect screening tool was used to measure cognitive function, and the St. George's respiratory questionnaire (SGRQ) to assess disease-specific QoL.DemTect scores were < 9 points in 1.6% of patients and < 13 points in 12% when using the original evaluation algorithm distinguishing between < 60 or > =60 years of age. For statistical reasons, we used the average of both algorithms independent of age in all subsequent analyses. The DemTect scores were associated with oxygen content, 6-min-walking distance (6-MWD), C-reactive protein (CRP), modified Medical Research Council dyspnoea scale (mMRC) and the SGRQ impact score. Conversely, the SGRQ impact score was independently associated with 6-MWD, FVC, mMRC and DemTect. These results were combined into a path analysis model to account for direct and indirect effects. The DemTect score had a small, but independent impact on QoL, irrespective of the inclusion of COPD-specific influencing factors or a diagnosis of cognitive impairment.We conclude that in patients with stable COPD lower oxygen content of blood as a measure of peripheral oxygen supply, lower exercise capacity in terms of 6-MWD, and higher CRP levels were associated with reduced cognitive capacity. Furthermore, a reduction in cognitive capacity was associated with reduced disease-specific quality of life. As a potential clinical implication of this work, we suggest to screen especially patients with low oxygen content and low 6-MWD for cognitive impairment. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
30. Effect of COPD severity and comorbidities on the result of the PHQ-9 tool for the diagnosis of depression: results from the COSYCONET cohort study.
- Author
-
von Siemens, Sarah Marietta, Jörres, Rudolf A., Behr, Jürgen, Alter, Peter, Lutter, Johanna, Lucke, Tanja, Söhler, Sandra, Welte, Tobias, Watz, Henrik, Vogelmeier, Claus F., Trudzinski, Franziska, Rief, Winfried, Herbig, Britta, Kahnert, Kathrin, and COSYCONET study group
- Subjects
COMORBIDITY ,INHALERS ,OBSTRUCTIVE lung diseases ,MEDICAL research ,PATHOLOGICAL psychology ,GENERAL Health Questionnaire ,COHORT analysis - Abstract
The diagnosis of depression, a frequent comorbidity of chronic obstructive pulmonary disease (COPD), is often supported by questionnaires, such as the Patient Health Questionnaire 9 (PHQ-9). It is unknown to which extent its single questions are affected by the clinical characteristics of COPD patients.We addressed this question in 2255 GOLD grade 1-4 patients from the COSYCONET (COPD and Systemic Consequences - Comorbidities Network) COPD cohort. The dependence on COPD severity was assessed using symptoms, exacerbation risk (GOLD A-D; modified Medical Research Council dyspnoea scale (mMRC)), and frequent comorbidities as predictors of PHQ-9 results, while including age, gender, body mass index (BMI) and smoking habits as covariates.Symptoms and exacerbation risk were associated with depression in an additive manner, with mean elevations in the PHQ-9 sum score by 2.75 and 1.44 points, respectively. Asthma, sleep apnoea, gastrointestinal disorders, osteoporosis and arthritis were linked to increases by 0.8 to 1.3 points. Overall, the COPD characteristics contributed to the mean PHQ-9 score by increases from 4.5 or 5.2 to 6.3 points, respectively, when either taking GOLD A as reference or the absence of comorbidities. This finding was independent of the diagnosis of mental disorder or the intake of antidepressants. The presence of COPD led to an increase in the proportion of scores indicating depression from 12 to 22%. Single item analysis revealed homogenous effects regarding GOLD groups, but heterogeneous effects regarding GOLD grades.These findings indicate specific effects of COPD severity on the PHQ-9 depression score, especially symptoms and exacerbation risk, explaining the high prevalence of depression in COPD. Alternative explanations like an overlap of COPD severity and PHQ-9 items are discussed. Of note, we also found COPD treatment effects on depression scores. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
31. [What have we learned from the German COPD cohort COSYCONET and where do we go from here?]
- Author
-
Kahnert K, Fischer C, Alter P, Trudzinski F, Welte T, Behr J, Herth F, Kauczor HU, Bals R, Watz H, Rabe K, Söhler S, Kokot I, Vogelmeier C, and Jörres R
- Subjects
- Humans, Comorbidity, Follow-Up Studies, Datasets as Topic, Pulmonary Disease, Chronic Obstructive diagnosis, Pulmonary Disease, Chronic Obstructive epidemiology, Pulmonary Disease, Chronic Obstructive drug therapy
- Abstract
COSYCONET 1 is the only German COPD cohort which is large enough to be internationally comparable. The recruitment, which started in 2010 and ended in December 2013, comprised 2741 patients with the diagnosis of COPD who were subsequently investigated in regular follow-up visits. All visits included a comprehensive functional and clinical characterisation. On the basis of this detailed data set, it was possible to address a large number of clinical questions. These questions ranged from the prescription of medication, the detailed analysis of comorbidities, in particular cardiovascular disease, and biomarker assessment to radiological and health-economic aspects. Currently, more than 60 publications of COSYCONET data are internationally available. The present overview provides a description of all the results that were obtained, focussing on the relationship between different clinical and functional aspects as well as their potential practical consequences. In addition, information on the follow-up study COSYCONET 2 is given., Competing Interests: Kathrin Kahnert berichtet persönliche Einnahmen über Vortragstätigkeiten der Fa. Astra Zeneca und GSK, welche nicht in Zusammenhang mit der COSYCONET-Studie stehen. Carolina Fischer, Jürgen Behr, Rudolf Jörres, Felix, Herth, Sandra Söhler, Henrik Watz, Inge Kokot, Peter Alter berichten keine Interessenskonflikte. Klaus Rabe berichtet persönliche Einnahmen für Vortragstätigkeiten von Astra Zencea, Boehringer Ingelheim, Chiesie Pharmaceuticals, Novartis, Sanofi & Regeneron, GlaxoSmithKline, Berlin Chemie, Roche Pharma sowie die Teilnahme an Advisory Boards bei Astra Zeneca, Boerhinger Ingelheim und Sanofi & Regeneron, welche nicht in Zusammenhang mit der COSYCONET-Studie stehen. Claus Vogelmeier berichtet über Verträge zwischen dem BMBF, Astra Zeneca, Boehringer Ingelheim, Chiesie, CSL Behring, GlaxoSmithKline, Grifols, Novartis und der Philipps-Universität Marburg, zudem persönliche Einnahmen über Vortragstätigkeiten/Beratungen bei den Firmen Aerogen, Astra Zeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GlaxoSmithKline, Insmed Menarini, Novartis, Nuvaira, Insmed Menarini, außerhalb der vorliegenden Arbeit. Franziska Trudzinski berichtet persönliche Einnahmen über Vortragstätigkeiten der Fa. Boehringer Ingelheim, Chiesie, GlaxoSmithKline, Grifols, Novartis, CSL Behring, welche nicht in Zusammenhang mit der COSYCONET-Studie stehen. Tobias Welte berichtet über Verträge zwischen dem BMBF, GSK, Novartis, Astra Zeneca, Boehringer Ingelheim und der Medizinischen Hochschule Hannover, zudem persönliche Einnahmen über Vortragstätigkeiten/Beratungen für Astra Zeneca, Berlin-Chemie, Boehringer Ingelheim, Chiesie, GSK, Novartis außerhalb der vorliegenden Arbeit. Hans-Ulrich Kauczor berichtet Unterstützung der Fa. Bayer an die Universität Heidelberg (Verbrauchsmaterial), Verträge zwischen den Fa. Philips, Siemens und Boehringer Ingelheim zu der Universität Heidelberg, ferner persönliche Einnahme über Vortrags- und Beratertätigkeiten bei Siemens, Philips, Boehringer Ingelheim, MSD, Sanofi außerhalb der hier eingereichten Arbeit. Robert Bals berichtet persönliche Einnahmen über Vortrags- und Beratertätigkeiten von AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Grifols, Novartis, CSL Behring sowie Fördermittel für das Institut des BMBF, des Competence Network Asthma and COPD (ASCONET), Sander Stiftung, Schwiete Stiftung, Krebshilfe, Mukoviszidose e.V. außerhalb der eingereichten Arbeit., (The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).)
- Published
- 2023
- Full Text
- View/download PDF
32. Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort.
- Author
-
Kahnert K, Lucke T, Biertz F, Lechner A, Watz H, Alter P, Bals R, Behr J, Holle R, Huber RM, Karrasch S, Stubbe B, Wacker M, Söhler S, Wouters EF, Vogelmeier C, and Jörres RA
- Subjects
- Aged, Carbon Monoxide, Cohort Studies, Comorbidity, Diabetes Mellitus blood, Female, Germany epidemiology, Humans, Male, Middle Aged, Prevalence, Pulmonary Disease, Chronic Obstructive blood, Reproducibility of Results, Risk Factors, Sensitivity and Specificity, Carbon Dioxide blood, Diabetes Mellitus diagnosis, Diabetes Mellitus epidemiology, Pulmonary Diffusing Capacity, Pulmonary Disease, Chronic Obstructive diagnosis, Pulmonary Disease, Chronic Obstructive epidemiology
- Abstract
Background: An impairment of CO diffusing capacity has been shown in diabetic patients without lung disease. We analyzed how diffusing capacity in patients with COPD is affected by the concurrent diagnosis of diabetes., Methods: Data from the initial visit of the German COPD cohort COSYCONET were used for analysis. 2575 patients with complete lung function data were included, among them 358 defined as diabetics with a reported physician diagnosis of diabetes and/or specific medication. Pairwise comparisons between groups and multivariate regression models were used to identify variables predicting the CO transfer factor (TLCO%pred) and the transfer coefficient (KCO%pred)., Results: COPD patients with diabetes differed from those without diabetes regarding lung function, anthropometric, clinical and laboratory parameters. Moreover, gender was an important covariate. After correction for lung function, gender and body mass index (BMI), TLCO%pred did not significantly differ between patients with and without diabetes. The results for the transfer coefficient KCO were similar, demonstrating an important role of the confounding factors RV%pred, TLC%pred, ITGV%pred, FEV
1 %pred, FEV1 /FVC, age, packyears, creatinine and BMI. There was not even a tendency towards lower values in diabetes., Conclusion: The analysis of data from a COPD cohort showed no significant differences of CO transport parameters between COPD patients with and without diabetes, if BMI, gender and the reduction in lung volumes were taken into account. This result is in contrast to observations in lung-healthy subjects with diabetes and raises the question which factors, among them potential anti-inflammatory effects of anti-diabetes medication are responsible for this finding.- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.